Policy / Pricing Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is Chilling BioSpaceAs Big Pharma companies consider foregoing European drug launches to avoid reducing drug prices in the U.S.Policy / PricingRead full story pharminent April 2, 2026 (Last updated: April 2, 2026) BioSpace As Big Pharma companies consider foregoing European drug launches to avoid reducing drug prices in the U.S. Policy / PricingRead full story Post navigation Previous: Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow EnrollmentNext: ACC 2026: sotatercept meta-analysis backs disease-modifying role in PAH Related Stories Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026 Policy / Pricing Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain pharminent August 13, 2026 Policy / Pricing Trump signs order that nearly halves childhood immunisation coverage pharminent August 11, 2026
